Medicare Coverage Might Make LVADs Attractive Acquisition Targets
This article was originally published in The Gray Sheet
Executive Summary
Large cardiovascular device firms may seek to acquire or enter distribution agreements with LVAD developers, following MCAC's positive review of left-ventricular assist devices as a destination therapy
You may also be interested in...
Medicare LVAD “Category B” Coverage Critical To Non-Pulsatile Device Firms
CMS' imminent coverage decision on permanent implantation of left-ventricular assist devices may be limited to FDA-approved pulsatile designs
Medicare LVAD “Category B” Coverage Critical To Non-Pulsatile Device Firms
CMS' imminent coverage decision on permanent implantation of left-ventricular assist devices may be limited to FDA-approved pulsatile designs
WorldHeart HeartSaver R&D Consolidation: 25% Personnel Cut Planned
WorldHeart's plan to merge the HeartSaverVAD and HeartSaverVADII development programs will save $10 mil. per year and help the firm reach profitability by 2004, the left-ventricular assist device maker predicts